Clinical Trial Search

Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants

Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates

Primary: Exploratory Outcomes From Digital Photography — 17; 7 Participants

Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7 — 78.6; 84.4 Percentage of Patients

Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants

Primary: Clinical Resolution — 167; 147 Participants

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 — 74.9; 65.2 Percentage of Patients

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 — 51.8; 41.3 Percentage of Patients

Primary: Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 5 — 111; 0; 95 Participants — p=0.127

Primary: Clinical Cure Rate — 37; 31; 27; 33 Participants — p=0.0137

Primary: Number of Women Diagnosed With C. Trachomatis and N. Gonorrhoeae Infection at Post-delivery — 2; 23 Participants

Primary: The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3 — 48; 29 participants

Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community

Primary: Complete Clinical Resolution — 9; 0 Participants

Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis — 90; 63 Participants

Primary: Solicited Local Injection Site Reactions — 2; 8; 3; 9 Participants — p=1

Primary: Clinical Cure at the Day 4 (EOT)/Exit Visit — 62.5; 50.6 percentage of subjects

Primary: Time Taken for a Complete Resolution of the Chalaziosis — 51.2; 28.4 days

Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03

Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale

Primary: Percent Change From Peak Viral Load — 1.9; 13.2 Percent of peak Viral Load — p=0.02

Primary: Change From Baseline Bacterial Culture — 30; 16; 26; 29 cultures — p=0.002

Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants

Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale

Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047

Primary: Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis — 71; 59 Participants — p=0.2219

Primary: Number of Participants With Normal Physical Examination of the Eye — 49; 37 participants

Primary: Microbiological Cure Rate — 94.9; 94.6 percentage of participants cured

Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale